147 results about "Alveolar lavage fluid" patented technology

The invention belongs to the technical field of virus detection, and particularly relates to a primer, probe, test kit and method for real-time fluorescent quantitative PCR detection of novel coronavirus 2019-nCoV. A single-tube double-fluorescence channel is adopted to simultaneously detect the existence of the novel coronavirus 2019-nCoV and reference gene Rnase P, and the existence of the novelcoronavirus 2019-nCoV RNA in specimens such as alveolar lavage fluid, nasopharyngeal swab, whole blood, serum, feces and tissues can be detected. The method is short in detection time period, and issuitable for clinical and bedside rapid detection of diagnosis; the virus detection specificity is high, and the accuracy is high; virus qualitative analysis and quantitative analysis are carried out,and the quantitative linear range is good; the detection sensitivity is high; the experimental result is good in repeatability and high in precision; and the reference gene is added into a detectionsystem, so that the quality of the whole process of extracting and amplifying the sample can be monitored through the detection result of the reference gene.

The invention relates to a nucleic acid detection kit for novel coronavirus COVID-19. The kit comprises a first primer pair and a first probe which correspond to Cov-n, and a second primer pair and asecond probe which correspond to Cov-ORF1ab. The kit disclosed by the invention can be used for simultaneously carry out multiple-gene and multiple-site detection on the novel coronavirus, so that thedetection accuracy is improved; and in addition, when the multiple fluorescence PCR reaction is carried out, novel coronavirus detection information can be provided through one-time detection within70 minutes, so that the diagnosis time of the novel coronavirus COVID-19 is shortened. The kit can be used for in vitro qualitatively detecting throat swabs, sputum and bronchoalveolar lavage fluid samples of suspected pneumonia cases infected by the novel coronavirus, suspected aggregated case patients, and other diagnosis people who are required to perform novel coronavirus infection diagnosis or identification.

The invention relates to a kit for detecting novel coronavirus N protein and an application of the kit. The kit comprises (1) one antibody capable of being bound to the novel coronavirus N protein, and (2) the other antibody marked by a marker and capable of being bound to the novel coronavirus N protein when the novel coronavirus N protein can be bound to (1) to limit the antibody. The using method of the kit comprises the step of determining whether a patient suffers from the novel coronavirus pneumonia or not by detecting the level of the novel coronavirus N protein in an individual sample.The kit for detecting the novel coronavirus N protein provided by the invention can be used for detecting the coronavirus N protein in nasopharynx swabs, oropharynx swabs, alveolar lavage fluids, serum, plasma, whole blood, sputum, oral swabs or saliva samples so as to be used for diagnosing novel coronavirus pneumonia.

The invention relates to an immunochromatographic kit for rapidly detecting novel coronavirus N protein as well as a preparation method and application of the immunochromatographic kit. The immunochromatographic kit comprises a test strip, the test strip comprises a detection line and a quality control line, the detection line is coated with an anti-novel coronavirus N protein antibody, and the quality control line is coated with a goat anti-rabbit polyclonal antibody. The immunochromatographic kit for rapidly detecting the novel coronavirus N protein provided by the invention can be used fordetecting the novel coronavirus N protein in a nasopharynx swab, an oropharynx swab, an alveolar lavage fluid, an oral swab or a saliva sample so as to be used for diagnosing novel coronavirus pneumonia.

The present invention relates to a method of predicting the risk of a subject developing a cardiovascular event, comprising determining the presence of a biomarker that is indicative of the risk of developing a cardiovascular event in exosomes from the subject. The exosomes are suitably isolated from a body fluid selected from serum, plasma, blood, urine, amniotic fluid, malignant ascites, bronchoalveolar lavage fluid, synovial fluid, breast milk, saliva, in particular serum. The biomarker is selected from the proteins Vitronectin, Serpin F2, CD14, Cystatin C, Plasminogen, Nidogen 2 or any combination of two or more of these proteins.

The invention discloses novel coronavirus 2019-nCoV fluorescent RPA detection primers, a probe, a kit and a method. The kit comprises novel coronavirus 2019-nCoV specific primers shown in SEQ ID NO. 1-2 and a probe shown in SEQ ID NO. 3. According to the invention, the existence of the novel coronavirus 2019-nCoV ORF1ab gene and the internal reference gene RNase P is simultaneously detected by adopting a single-tube double-fluorescence channel, and the existence of the novel coronavirus 2019-nCoV RNA in pulmonary alveolar lavage fluid, nasal swab, pharyngeal swab, sputum and other samples canbe detected. The method is short in detection time and suitable for clinical and bedside virus nucleic acid rapid screening, the kit has extremely high sensitivity and specificity, an internal reference gene is added into the detection system, and quality monitoring is performed on the extraction and amplification process of the sample according to the detection result of the internal reference gene.

The invention relates to the technical field of medicines, and particularly relates to cryptotanshinone for preventing and treating pulmonary fibrosis and an application thereof. The cryptotanshinone (I) is quinone diterpene extracted from the root part of salviae miltiorrhizae; the modern pharmacological research shows that the cryptotanshinone has a bacteriostatic effect, an anti-inflammatory effect and a hormone-like pharmacologic effect, and is clinically used for treating myocardial fibrosis, lung acute injury and arthritis, can be used for preventing and/or treating a pulmonary fibrosis disease, can also be used for preparing medicines for reducing body weight of a pulmonary fibrosis rat, a lung coefficient and the content of hydroxyproline in tissue and can be used for preparing the medicines for reducing the content of IL-1beta, IL-6 and TNF-alpha in a bronchoalveolar lavage liquid and the medicines of effecting the pathogeny structure of pulmonary fibrosis tissue of the rat. The formula (I) is as shown in the specification.

The invention discloses application of Aspergillus fumigatus annexin anxC4 gene (anxC4 gene). The anxC4 gene can be used as an Aspergillus fumigatus detection target. The invention also discloses a LAMP (loop-mediated isothermal amplification) kit designed according to the specific conserved sequence of the anxC4 gene and special primers thereof, and an Aspergillus fumigatus real-time fluorescent quantitative PCR (polymerase chain reaction) detection kit and primers and TaqMan probes thereof. The technique can be used for qualitatively detecting Aspergillus fumigatus components in phlegm, blood, bronchus alveoli douche and other samples to be detected, and can be used for quickly and conveniently detecting Aspergillus fumigatus under isothermal conditions in a high-efficiency high-specificity high-sensitivity way.

The invention discloses lactobacillus reuteri capable of alleviating allergic asthma and application thereof and belongs to the technical field of medicines. The lactobacillus reuteri has an effect ofrelieving allergic asthma, which is embodied by: (1) significantly reducing lung inflammation in mice with allergic asthma; (2) significantly inhibiting the generation of dust mite specific immunoglobulin IgG1 in serum of allergic asthma mice; (3) significantly reduced the contents of IL-5 and IL-13 in alveolar lavage fluid of mice with allergic asthma; (4) significantly reducing the content of IL-17A in alveolar lavage fluid of mice with allergic asthma, and thus the lactobacillus reuteri has great application prospects in the preparation of products for preventing and/or treating allergic asthma.

The invention provides a kit for multiple detection of respiratory pathogens. Specifically, according to the kit, a PCR amplification system of multiple respiratory pathogens is designed and verifiedby the experiment, a multiple fluorescent PCR amplification system for detecting the multiple respiratory pathogens is obtained, and three respiratory pathogens can be detected simultaneously by a single system. The kit has high sensitivity and specificity, and according to the kit, the multiple respiratory pathogens in samples of nasopharynx swab, alveolar lavage fluid, sputum and the like can bedetected and analyzed quickly.

This invention pertains to the discovery that Parathyroid Hormone-related Protein (PTHrP) can be detect and/or stage, and/or treat chronic lung diseases. In particular, it was discovered that PTHrP levels in broncho-alveolar lavage are indicative of lung “health”, and “disease”, and can be used to predict lung disease in patients at risk of chronic lung disease and/or to evaluate the efficacy of a ventilation regime.

The invention provides a kit for detecting SARS-CoV-2 novel coronavirus nucleic acid at a constant temperature by using an enzyme digestion probe. The kit comprises an isothermal amplification primerfor detecting an ORF1ab gene of SARS-CoV-2 novel coronavirus and a corresponding RNA-containing base probe capable of being digested by RNase H, wherein the left end and the right end of an RNA base of the base probe are respectively marked with a reporter fluorophore and a quencher. By utilizing the efficient isothermal amplification primer and the probe, constant-temperature multiple detection can be carried out on the SARS-CoV-2 novel coronavirus, and the kit has high sensitivity and high specificity. The novel coronavirus nucleic acid detection kit disclosed by the invention has high sensitivity and specificity, can be used for detecting throat swabs, alveolar lavage fluid and sputum samples of suspected novel coronavirus pneumonia cases, suspected aggregated case patients and other patients needing novel coronavirus infection diagnosis or differential diagnosis, and has the characteristics of simplicity, convenience, quickness and accuracy.

The invention provides a primer composition for detecting legionella in clinical and environmental specimens. The primer composition comprises a pair of primers (shown in the Seq ID No.1-2) for PCR specific amplification of a gene mip and a pair of primers (shown in the Seq ID No.3-4) for PCR specific amplification of 16S rRNA. The invention also provides a detection kit containing the primer composition. A test on 320 groups of phlegm and alveolar irrigation solutions of pneumonia patients and 210 groups of environmental water specimens proves that the primer composition has singularity of 100% and a lowest detection limit of 2*10<1> cfu/ml. The dual PCR system can be successfully used in bacterial strain identification and clinical and environmental specimen detection. The PCR detection method built based on the dual PCR system has the characteristics of simpleness, fastness and reliability and can be widely used in epidemiology preliminary investigation, environmental water monitoring and clinical specimen detection.

The invention discloses an application of eupatorium sesquiterpene components in preparing a drug for resisting acute lung injury. Eupatorium sesquiterpene components are made into a veterinary drug. A technical solution provided by the invention comprises the steps of making the eupatorium sesquiterpene componentsinto a veterinary drug; inducing acute lung injury in mice by using lipopolysaccharide (LPS) in a manner of in-vivo dosing to the mice; then determining a lung wet/dry ratio of the mice with the acute lung injury, the content of nitric oxide (NO) and protein in a bronchoalveolar lavage fluid (BALF); detecting activities of myeloperoxidase (MPO) and superoxide dismutase (SOD) in lung tissue homogenate, the content of tumor necrosis factor-alpha (TN-alpha), interleukin-6 (IL-6) and interleukin-1[beta] (IL-1[beta]) in the BALF and the content of complement C3 and C3c in blood serum; and observing pathological changes of lung tissues of the mice after H&E staining. Results show that eupatorium sesquiterpene components of eupalinolide F, eupalinolide G, eupalinolide H, eupalinolide I and eupalinolide K have activity for resisting the acute lung injury.

The invention belongs to the pharmaceutical field, relates to a novel medicinal use of calycosin-7-glucoside and especially relates to a use of calycosin-7-glucoside in preparation of drugs for treating asthma and especially for treating allergic asthma. The results of an in-vivo animal experiment and an in-vitro CD4+T cell culture experiment show that calycosin-7-glucoside has effects on an ovalbumin-induced mouse asthma model and CD4+T cells isolated from spleen, and can significantly reduce airway hyperresponsiveness of asthmatic mice, inhibit airway inflammation, reduce the number of inflammatory cells in an alveolar lavage fluid, inhibit chemokine secretion, promote Th1 cell differentiation, inhibit IL-17A, promote IFN-gamma and IL-10 secretion and inhibit NF-kappa B activation. The calycosin-7-glucoside can be used as a single ingredient for preparation of drugs for treating asthma or allergic asthma.

The invention provides a kit for respiratory pathogen multiple nucleic acid detection. In specific, a multiple respiratory pathogen PCR amplification system is designed and verified with experiments to obtain a multiple fluorescence PCR amplification system for detecting a plurality of respiratory pathogens, and 9 respiratory pathogens can be detected simultaneously. The kit has high sensitivity and specificity, and can achieve rapid detection and analysis on multiple respiratory pathogens in nasopharyngeal swabs, alveolar fluid, sputum and other samples.

The invention belongs to the technical field of biological medicines and aims at improving the gene transfection efficiency by adopting nano-particles NoNPs released through cells. The nano-particles exist extensively in a biosystem and an extracellular circulatory system, such as bronchoalveolar lavage fluid, body fluid, blood, saliva, cow milk or urine. A non-virus gene transfection vector is doped with the nano-particles so that the DNA (Desoxvribose Nucleic Acid) carrying capacity of the gene transfection vector can be improved remarkably without increase of cytotoxicity. Experimental results indicate that the NONPs, which are extracted from the cow milk and added to the PEI gene transfection vector, are capable of remarkably improving the gene transfection efficiency under the circumstance of hardly increasing the cytotoxicity. The major use of the nano-particles is to serve as the gene transfection reagent which can be used for cell biology research, gene transfection preparation production, gene therapy and the like.

A safe, simple, convenient, low-pollution and good-repeatability extracting method of alveolar lavage fluid metagenome DNAs is provided. The method includes steps of liquefying a sample, crushing cells, isolating target DNAs, removing impurity proteins and salt ions, performing DNA adsorption and performing DNA elution. The method can increase the yield and purity of the metagenome DNAs and can meet PCR, DNA library construction, gene sequencing, and other molecular biological experiments.

The invention provides a combined detection method of flow cytometry in humoral cellular immunoassay, and relates to the technical field of immunoassay. The combined detection method of the flow cytometry in humoral cellular immunoassay comprises the following steps of: S1, collecting a humoral specimen; S2, evaluating the quality and quantity of specimens; S3, carrying out conventional cell population classification, multi-label immune typing, cytokine analysis and tumor marker inspection; and S4, carrying out result analysis. According to the combined detection method, a direct fluorescence labeling cell surface antibody and nucleic acid technology is combined with conventional cell examination and other methods to carry out combined detection analysis, such that the combined detection method can be used for detecting a variety of diseases such as benign and malignant tumors, inflammations, bacteria, tuberculosis infection and the like, has a wide disease detection range, and has high clinical diagnosis and identification significance; and various body fluids such as urine, sputum, alveolar lavage fluid, pleuroperitoneal fluid and dialysate can be adopted for detection, materials are convenient and simple to obtain, and the cost is low.

The invention discloses a method for preparing a pneumonia rat model and a model evaluation method, and belongs to the technical field of biology. The method for establishing the pneumonia rat model is non-invasive and safe to rats, does not damage other organs of rats in the whole process, and effectively avoids the death of the rats. Besides, the method has simple operation and high success rate. According to the pneumonia rat model established by the method, pseudomonas aeruginosa in bronchoalveolar lavage fluid is obviously increased, inflammatory factors IL-4 and TNF-alpha are obviously increased, the level of adhesion factor IFN-gamma is obviously reduced, and the number of leukocytes is obviously increased. Meanwhile, the lung index is also obviously increased, which indicates thatthe model is established well.

The invention provides a respiratory tract infection multiple detection reagent kit and detection method. Particularly, a multiplex respiratory tract pathogen PCR amplification system is designed and subjected to experimental verification, so that a multiplex fluorescent PCR amplification system for detecting various respiratory tract pathogens is obtained, and a single system can detect 3 kinds of respiratory tract pathogens at the same time. The reagent kit has high sensitivity and specificity. Through the reagent kit, quick detection and analysis of multiplex respiratory tract pathogens in samples of nasopharyngeal swabs, bronchoalveolar lavage fluid, phlegm and the like can be realized.

The invention relates to application of Faecalibacterium prausnitzii in relieving allergic asthma and rhinitis Th2 reaction, and belongs to the technical field of microorganisms and medicines. According to the application disclosed by the invention, the Faecalibacterium prausnitzii A2-165 is applied to relieving of allergic asthma and rhinitis, and the application is specifically embodied in that(1) the infiltration effect of memory inflammatory cells with lung pathological symptoms of mice with allergic asthma and rhinitis is remarkably improved; (2) the contents of IL-4, IL-5 and IL-13 in alveolar lavage fluid for the mice with allergic asthma and rhinitis are remarkably reduced; (3) the generation of dust mite specific immunoglobulin IgG1 in serum of the mice with allergic asthma and rhinitis is remarkably inhibited; and (4) the ratio of Tregs in the spleen is remarkably increased, so that the Faecalibacterium prausnitzii A2-165 has a huge application prospect in the preparation ofa product for prevention and/or treatment.

The invention discloses a novel method for detecting pathogenic microorganisms. The method comprises: a collection step of samples such as cerebrospinal fluid and alveolar lavage fluid; a collection steps of peripheral blood samples; a DNA extraction step; a library construction step; a sequencing step; and an analysis step. The DNA extraction step comprises: taking 400 [mu]l sample for detection,adding reaction reagents of buffer GB, Lysis Enzyme K, RNA, Carrier to the sample, conducting reaction at 56 DEG C for 10 minutes to obtain a reaction solution, purifying the reaction solution by silica gel membrane adsorption column to remove salt ions and organic reagents, and obtaining DNA with total amount and purity meeting the requirements. The library construction step comprises: conducting terminal repair, linker connection, library amplification and enrichment, purification and quality control of the DNA to complete the library construction. The sequencing step comprises: denaturingthe library into a single strand by NaOH, then binding the library to a sequencing chip, enriching each single strand DNA into a cluster by bridge amplification, and obtaining sequencing data by usingIllumina SBS sequencing method to read the sequence. The analysis step comprises: filtering the sequencing data, removing the human source and the linker sequence, and comparing the remaining data with a microbial reference database.

The invention relates to application of a euphorbia jolkini lactone B derivative in a drug for treating a chronic obstructive pulmonary disease, and belongs to the field of medicines. In the application, a pharmacodynamic experiment is performed on a mouse model with the chronic obstructive pulmonary disease by adopting a compound; a result shows that HJB-1 has an obvious effect of improving lungtissue lesions of the mouse with the chronic obstructive pulmonary disease and a function of decreasing the number of inflammatory cells in bronchoalveolar lavage fluid of the mouse with the chronic obstructive pulmonary disease; the euphorbia jolkini lactone B derivative is used for developing the drug for treating the chronic obstructive pulmonary disease.

The invention relates to an application of timosaponin N in preparation of a medicine for preventing and treating pulmonary fibrosis. In the embodiment of the invention, the timosaponin N can remarkably improve the weight and lung index of a bleomycin pulmonary fibrosis model rat, and remarkably reduce biochemical indicators closely related to the pulmonary fibrosis, such as the content of hydroxyproline in lung tissues and the levels of TGF-beta and TNF-alpha in pulmonary alveolar lavage fluid. In addition, the indexes related to the pulmonary fibrosis can be further improved synergisticallyby combining timosaponin N with pirfenidone. Therefore, the timosaponin N or the combination of the timosaponin N and the pirfenidone can effectively improve a pulmonary fibrosis degree of a pulmonaryfibrosis model rat, have the prospect of being developed into the anti-pulmonary fibrosis medicine, and have important social benefits and economic benefits.